Breaking AI & Tech News Analyzed

Sam Neill, the veteran actor celebrated for his memorable performances on screen, is set to answer readers' questions in an upcoming interview with The Guardian. Neill's iconic roles include his portrayal in Jurassic Park, where he famously removes his sunglasses and gazes at a towering Brachiosaurus, a scene that has become etched in cinematic history.Born in Northern Ireland and raised in New Zealand, Neill's diverse filmography showcases his versatility as an actor. He has appeared in a range of films, from period dramas like My Brilliant Career to thrillers such as Dead Calm, which is set to be released in 4K later this year. His recent projects include Godzilla x Kong: Supernova, alongside Kaitlyn Dever and Matthew Modine.Neill's career has been marked by his ability to take on idiosyncratic, director-led projects, often playing characters with a unique blend of gruffness and warmth. His performances in Sweet Country and Rams have been particularly noted for their depth and nuance.In addition to his film work, Neill has also made headlines for his memoir, Did I Ever Tell You This?, in which he openly discusses his experience with stage-three blood cancer and his journey towards remission. When asked about his mortality, Neill expressed a pragmatic view, stating, “I’m not afraid to die, but it would annoy me”.Readers are invited to post their questions for Sam Neill by 6pm BST, Thursday 16 April, and The Guardian will publish his answers in their reader interview series. This provides a unique opportunity for fans to engage with one of cinema's most beloved actors and gain insight into his life and career.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

Australian sprint prodigy Gout Gout stunned the athletics community on Sunday at the national championships in Sydney, clocking a legal 19.67 seconds over 200 m. The performance not only smashed his own previous national record of 20.02 seconds but also made him the first Australian to dip below the coveted 20‑second barrier. Gout’s coach and mentor, Di Sheppard, summed up the achievement with a wry grin: “How long’s a piece of string?” – a nod to the seemingly limitless potential the teenager now displays. The run placed Gout ahead of his compatriot Aidan Murphy, who finished a close second, and sparked immediate comparisons with Jamaican legend Usain Bolt. While Bolt’s all‑time best stands at 19.19 seconds (set in 2009), Gout’s 19.67 at the age of 18 already eclipses the Jamaican great’s performance at the same age, according to his camp. Only one other under‑20 athlete has ever posted a faster time – Erriyon Knighton – whose 2022 effort remains unratified after a subsequent ban. James Templeton, the 18‑year‑old’s manager, said the result was “thrilling but not shocking”, recalling that Gout ran 19.84 seconds the previous year with a marginal wind assistance, a time the team always considered his realistic benchmark. Gout himself has been fixated on breaking the sub‑20 mark ever since an illegal run earlier in his career. “I wrote down 19.75 and kept telling myself I’d hit it,” he explained. “Then I hit 19.67 – gotta love it.” Despite the historic run, the teenager shows no intention of slowing down. “I’ve just turned 18, so I definitely think I can go faster,” he said. “It’s about building consistency and there’s no pressure – I’m the only one out there.” Looking ahead, Gout will compete in the under‑20 junior championships this week, opting to skip the 200 m in Queensland and focus on the 100 m. He will then travel overseas for a high‑profile showdown with Olympic champion Noah Lyles over 150 m at the Golden Spike meet in Ostrava, scheduled for June. Should Gout continue his upward trajectory, the athletics world may soon witness a new challenger to Bolt’s long‑standing age‑group record, reshaping expectations for the next generation of sprint talent.

The highly anticipated third and final season of Euphoria premieres on Monday at 9pm on Sky Atlantic. The series, created by Sam Levinson, follows the lives of a group of high school students as they navigate love, friendship, and identity.The new season stars Zendaya, Jacob Elordi, and Sydney Sweeney, who have all become major Hollywood stars since the show's debut. The story picks up five years after high school, with the characters now in their early 20s. Previews are scarce, but it's known that Cassie and Nate are married, Jules is in art school and is a 'sugar baby', and Rue is involved in some shady business in Mexico.Other TV shows airing tonight include Miriam Margolyes Made Me Me on BBC Two, Great Japanese Railway Journeys on BBC Two, Missed Call on Channel 5, Charmain and the Prophet on BBC Two, and DTF St Louis on Sky Atlantic.

The ongoing conflict in Iran has created a perilous situation where the threat of nuclear war and climate disruption have converged into a single, catastrophic crisis. This crisis will persist long after the war subsides, emphasizing the need for immediate and decisive action. For over a decade, climate change has been recognized not just as an environmental issue but as a fundamental threat to national and global security. The current situation demands that governments conduct thorough risk assessments and treat climate change with the same urgency as military threats. The war on Iran has several alarming features: Unilateral action: The US and Israel launched a large-scale war against a sovereign nation without consulting major allies, creating a diplomatically isolated conflict with no clear exit strategy. Escalation threats: There are credible threats of escalation from both sides, with Donald Trump issuing ultimatums and Iran threatening to target critical infrastructure. Catastrophic miscalculation: The conditions for miscalculation are ripe, with erratic leadership, intelligence failures, and extreme pressure on decision-makers. The conflict has significant implications: Global energy shock: The closure of the Strait of Hormuz has caused an acute global energy shock, with higher oil prices likely to accelerate inflation and economic instability. Climate impact: The war is consuming military resources and political attention, with no climate dividend, and may pressure countries to extend fossil fuel use. Australia, as a regional power and signatory to the NPT, has responsibilities to the international order. The author, Admiral Chris Barrie, calls on the Australian government to take four key steps: Conduct and release a nuclear escalation risk assessment. Use diplomatic channels to counsel restraint. Refuse any form of complicity in nuclear use. Champion de-escalation at the NPT review conference. Australia can play a crucial role in addressing these threats by acting on evidence, speaking plainly about risks, and leading rather than following events.

Gout Gout, an 18‑year‑old sprint prodigy, delivered a historic performance at the Australian Athletics Championships in Sydney, finishing the 200 m in 19.67 seconds. The time not only secured his victory but also established a new world Under‑20 record, surpassing the previous mark held by Erriyon Knighton. The achievement marks the first occasion an Australian has legally broken the 20‑second barrier in the 200 m, with a permissible tailwind of +1.7 m/s. Gout’s run also eclipses the age‑grade benchmark set by Usain Bolt, who recorded 19.93 seconds at 19 years old in 2004. Fellow countryman Aidan Murphy finished second, posting 19.88 seconds, making the two performances the fastest of the year. Both athletes benefited from the same legal wind assistance, underscoring a surge in Australian sprinting depth. Speaking at the Sydney Olympic Park Athletic Centre, Gout emphasized the competitive environment: "Competing with world‑class athletes in Australia pushes us to new limits. Having two Australians under 20 seconds is extraordinary." The record also improves on Gout’s own national best of 20.02 seconds set the previous season, and it is his first sub‑20‑second run under legal wind conditions. Last year he had recorded 19.84 seconds with a wind‑assisted tailwind. Gout’s rise began in 2024 when he ran 20.04 seconds at the Australian All Schools Athletics Championships, breaking Peter Norman’s long‑standing national record of 20.06 seconds from the 1968 Olympics. His rapid progression has drawn international attention, with analysts comparing his explosive style to that of Bolt. On the final day of the meet, Gout’s main rival, Lachlan Kennedy, withdrew from the 200 m to manage his workload, though he later claimed the 100 m title with a 9.96‑second dash, becoming the first Australian to break ten seconds on home soil. Born to South Sudanese immigrants, Gout’s background adds a compelling narrative to his athletic success, highlighting the multicultural fabric of Australian sport. With the world record now in his hands, Gout expressed confidence about his future: "Running this time legally lifts a huge weight off my shoulders. I’m ready for the next challenges."

Paddington: The Musical was the big winner at the Olivier Awards, taking home seven prizes, including Best New Musical. The show, which features music and lyrics by Tom Fletcher and a book by Jessica Swale, dominated the ceremony at the Royal Albert Hall in London.The duo who play Paddington, James Hameed and Arti Shah, won Best Actor in a Musical for their performances. The show's baddies, Tom Edden and Victoria Hamilton-Barritt, also won awards for Best Supporting Actor and Best Supporting Actress in a musical, respectively. Luke Sheppard was named Best Director for the production, which also picked up awards for Costume Design and Set Design.The ceremony was hosted by Nick Mohammed, who joked about being asked how he got the gig. Performances on stage included stars like Rachel Zegler, who won Best Actress in a Musical for Evita, and Fabian Aloise, who won Best Theatre Choreographer for Evita.Rosamund Pike won Best Actress for her performance in Inter Alia, while Paapa Essiedu won Best Supporting Actor for All My Sons. The awards also recognized regional theatre triumphs, including Kenrex and Punch.The Olivier Awards, overseen by the Society of London Theatre, celebrate the best in London theatre productions. This year's ceremony marked the 50th anniversary of the awards.

US Vice‑President JD Vance addressed a podium in Pakistan, confirming that after a marathon 21‑hour negotiation no settlement had been secured to end the conflict with Iran. Meanwhile, President Donald Trump was in Miami watching a mixed‑martial‑arts fight, a stark contrast that underscored the administration’s focus on spectacle over substantive diplomacy. The breakdown was not accidental. Washington insists Iran must relinquish any capacity to develop a nuclear weapon, whereas Tehran maintains its right to a civilian nuclear programme and rejects the notion of a weapons agenda. The US “final and best offer” demanded a complete surrender of that capability, a condition more akin to imposing victory than fostering negotiation. Compounding the impasse, the United States sought unrestricted navigation through the Strait of Hormuz, a critical artery for global energy supplies. Iran, however, pressed for transit fees, lifted sanctions, unfrozen assets, reparations, and a broader regional cease‑fire. The divergent demands meant that a single round of talks could not bridge the gap, resulting in negotiations devoid of trust and a war without a clear resolution. Historical wisdom, echoed by Winston Churchill’s famous remark that "jaw‑jaw is better than war‑war", highlights the high cost of continued fighting. Ironically, the current US‑Iran dispute revolves around a nuclear programme that was once restrained by a deal the Trump administration later abrogated, and a maritime route that the same administration helped ignite by launching the conflict. The fragile cease‑fire’s survival now hinges not only on Washington and Tehran but also on Israel’s expanding offensive in southern Lebanon against Hezbollah, an operation that has drawn accusations of war crimes and threatens to widen the regional conflagration. Financial markets are unlikely to react positively to recent developments. American voters are already feeling the impact of surging fuel prices, and Trump’s consideration of a naval blockade of the Strait of Hormuz could exacerbate the situation. Disrupting a route that carries roughly one‑fifth of global oil would push prices higher, with ripple effects far beyond the Gulf. The current cease‑fire is set to expire in just over a week. While diplomatic talks have not formally ended, a stalemate persists and the logic of escalation is gaining traction. Iran appears unlikely to concede, opting instead to test US resolve at sea. Seasonal heat may limit a full‑scale ground offensive for now, but the risk of a shift toward naval confrontations, airstrikes, and proxy warfare looms, offering no winners—only further loss.